drugset / Trial / NCT00707135
Rapamycin in Advanced Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.
Timeline
- Start
- 2005-06
- Primary completion
- 2008-09
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | — | — |